A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
Phase 1
Completed
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: Placebo-matched MoxifloxacinDrug: Placebo-matched CBP-307
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Connect Biopharma Australia Pty Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT04818229
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
🇺🇸Clinical Pharmacology of Miami (CPMI), LLC, Hialeah, Florida, United States
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Connect Biopharma Australia Pty Ltd
- Target Recruit Count
- 74
- Registration Number
- NCT04811469
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath